铁螯合治疗引发对转移性卵巢癌的先天免疫控制
本文报告FDA批准的铁螯合剂去铁酮可重编程卵巢癌细胞至免疫刺激状态,通过I型干扰素产生和NK细胞激活分子过表达实现。机制涉及胞质线粒体DNA的先天感知和核DNA损伤应答激活。去铁酮与化疗协同,通过增强I型干扰素应答驱动NK细胞依赖性控制转移性疾病,延长卵巢癌小鼠生存期。
要点
- 去铁酮将卵巢癌细胞重编程为免疫刺激状态,产生I型干扰素并过表达NK细胞激活分子。
- 去铁酮与化疗协同,通过增强I型干扰素应答驱动NK细胞依赖性控制转移性疾病。
- 铁螯合可能成为对当前T细胞中心疗法难治的恶性肿瘤的替代免疫治疗策略。
核心结论
- 铁螯合治疗利用FDA批准的药物在卵巢癌细胞中引发免疫原性应激反应,延缓转移性疾病进展并增强一线化疗效果。
研究设计与样本
- 本研究为实验性研究,使用FDA批准的铁螯合剂去铁酮处理卵巢癌细胞和小鼠模型。
主要发现
- 去铁酮将卵巢癌细胞重编程为以产生I型干扰素和过表达NK细胞激活分子为特征的免疫刺激状态。
- 去铁酮的上述效应由胞质线粒体DNA的先天感知和铁螯合触发的核DNA损伤应答 concomitantly 激活所驱动。
- 去铁酮与化疗协同,通过增强I型干扰素应答驱动NK细胞依赖性控制转移性疾病,延长卵巢癌小鼠生存期。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Iron accumulation in tumors contributes to disease progression and chemoresistance. Although targeting this process can influence various hallmarks of cancer, the immunomodulatory effects of iron chelation in the tumor microenvironment are unknown. Here, we report that treatment with deferiprone, an FDA-approved iron chelator, unleashes innate immune responses that restrain ovarian cancer. Deferiprone reprogrammed ovarian cancer cells toward an immunostimulatory state characterized by the production of type-I IFN and overexpression of molecules that activate NK cells. Mechanistically, these effects were driven by innate sensing of mitochondrial DNA in the cytosol and concomitant activation of nuclear DNA damage responses triggered upon iron chelation. Deferiprone synergized with chemotherapy and prolonged the survival of mice with ovarian cancer by bolstering type-I IFN responses that drove NK cell-dependent control of metastatic disease. Hence, iron chelation may represent an alternative immunotherapeutic strategy for malignancies that are refractory to current T-cell-centric modalities. Significance: This study uncovers that targeting dysregulated iron accumulation in ovarian tumors represents a major therapeutic opportunity. Iron chelation therapy using an FDA-approved agent causes immunogenic stress responses in ovarian cancer cells that delay metastatic disease progression and enhance the effects of first-line chemotherapy. See related commentary by Bell and Zou, p. 1771.
引用
- Sandoval TA, Salvagno C, Chae CS, et al. Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer. Cancer Discov. 2024. PMID: 39073085. doi:10.1158/2159-8290.CD-23-1451
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。